Methods for treating traumatic brain injury with amnion-derived cellular cytokine solution (ACCS) or amnion-derived multipotent progenitor (AMP) cells

• US 10,286,015 B2
• Filed: 04/25/2017
• Issued: 05/14/2019
• Est. Priority Date: 04/13/2007
• Status: Active Grant

• Current Assignee: Noveome Biotherapeutics, Inc
• Original Assignee: Noveome Biotherapeutics, Inc
• Inventors: Sing, George L, Marshall, Vivienne S
• Primary Examiner(s): Borgeest, Christina M
• Application Number:
  US15/496,133
• Publication Number:
  US 20170224740A1
• Time in Patent Office: 749 Days
• Field of Search: None
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/48 Reproductive organs
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61K 38/179 for growth factors; for growth regulators
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 38/1808 Epidermal growth factor [EGF] urogastrone
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 38/2292 Thymosin; Related peptides
• CPC Class Codes: A61K 38/30 Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 insulin-like growth factor binding protein A61K38/1754
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3878 Nerve tissue, brain, spinal cord, nerves, dura mater
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 2533/54 : Collagen; Gelatin
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.

Claims

1. A method for treating a closed-head traumatic brain injury in a patient in need thereof comprising the step of administering to the patient a therapeutically effective amount of a composition selected from the group consisting of Amnion-derived Cellular Cytokine Solution (ACCS) and Amnion-derived Multipotent Progenitor (AMP) cells.

2. The method of claim 1 wherein the ACCS is pooled ACCS.

3. The method of claim 1 wherein the closed-head traumatic brain injury is selected from the group consisting of Shaken Baby Syndrome, blast injury, blunt trauma, concussion, and concussion syndrome.

4. A method for relieving or ameliorating neurodegeneration in the brain caused by a closed-head traumatic brain injury in a patient in need thereof comprising the step of administering to the patient a therapeutically effective amount of a composition selected from the group consisting of ACCS or AMP cells.

5. The method of claim 4 wherein the ACCS is pooled ACCS.

6. The method of claim 4 wherein the closed-head traumatic brain injury is selected from the group consisting of Shaken Baby Syndrome, blast injury, blunt trauma, concussion, and concussion syndrome.